Ozmosi | Pegloxenatide Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Pegloxenatide

Alternative Names: Pegloxenatide, pex-168, pex168, pex 168
Clinical Status: Inactive
Latest Update: 2025-02-26
Latest Update Note: Clinical Trial Update

Product Description

For Type 2 Diabetes Mellitus

Mechanisms of Action: GLP-1 Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hansoh Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Type 2 Diabetes|Infertility|Obesity|Endometrial Hyperplasia

Phase 1: Type 2 Diabetes

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ChiCTR2100046705

 ChiCTR2100046705

N/A

Recruiting

Type 2 Diabetes

2021-06-30

NCT02461914

 PEX168-Ii

P1

Completed

Type 2 Diabetes

2015-12-12

2019-03-20

Treatments

NCT02472236

 PEX168-Ij

P1

Completed

Type 2 Diabetes

2015-09-24

2019-03-20

Treatments

NCT02447601

 PEX168-Ik

P1

Completed

Type 2 Diabetes

2015-05-14

2019-03-20

Treatments

NCT05172999

 NCT05172999

P3

Active, not recruiting

Obesity|Endometrial Hyperplasia|Infertility

2024-12-30

2025-02-28

Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments|Trial Status

NCT02477969

 PEX168-302

P3

Unknown status

Type 2 Diabetes

2016-06-22

2019-03-20

NCT02477865

 PEX168-301

P3

Unknown status

Type 2 Diabetes

2016-05-15

2019-03-22

Treatments

Recent News Events

Date

Type

Title

04/23/2024

PubMed

 Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.

03/07/2024

PubMed

 Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on "time in range" in patients with type 2 diabetes.

03/01/2024

PubMed

 Is polyethylene glycol loxenatide 100 mug the preferred glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus? A meta-analysis and trial sequential analysis.

03/17/2020

News Article

 Type 2 Diabetes Market Overview & Outlook, 2020 - SGLT-2 Inhibitors Hoping to Bolster Growth with Data & Label Additions for Pivotal HF and Chronic Kidney Disease (CKD) Trials

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions